focus -WSS

focus

author：comprehensive 2025-10-01 21:10:02 - browse：86759

Illustration fo a pink arrow pointing downward. -- biotech coverage from STAT — Adobe

SAN DIEGO — Ventyx Biosciences reported on Monday that it was ending development of an experimental drug for treating plaque psoriasis though it proved safe and moderately effective in a mid-stage trial. Within hours, the company’s stock tanked by more than 80%.

That’s because the company announced that the small molecule, VTX958, had not met the biotech’s internal goals to advance to the next phase of clinical development. Ventyx said it would end work on the drug, which targets the signaling molecule TYK2, as a treatment for psoriasis and psoriatic arthritis.

Shares in Ventyx plummeted from $14.09 at market close to as little as $2.72 during after-hours trading. In the process, the company’s market value dropped from $830 million to around $160 million. Ventyx is now trading below its cash balance, which was $300 million as of the end of September.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Drug for rare kidney disease narrowly misses mark in clinical trial

leisure time

explore

WSS

Kidney disease boosts cardiac arrest risk for Hispanics, Latinos

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Senators: Long

Bernie Sanders bashes nonprofit hospitals over their tax breaks

European regulators recommend Amylyx's ALS drug be rejected

STAT Readout: Today's biotech news includes Sana and Amylyx

hotspot

focus

knowledge

Medicare details structure of new drug price negotiation program

Bernie Sanders bashes nonprofit hospitals over their tax breaks

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Second xenotransplant done with gene

The cancer drug shortage isn’t new — and neither are the solutions

It's been 20 years since Dolly the sheep. Where's my clone?

23andMe had bad news about my health. I wish a person had delivered it

Takeaways from AdvaMed, the largest medical devices conference

23andMe had bad news about my health. I wish a person had delivered it

STAT Virtual Event: Putting AI to the Test

leisure time

Hearing on Medicare drug price negotiation gets unusually heated

Emergency workers more likely to restrain Black patients: study

Peter Marks talks Operation Warp Speed for Rare Diseases

Changes to biosimilar regulatory framework must prioritize patients

STAT Readout Newsletter: Today in biotech, life science news

CDC's new outbreak response network to include Northeastern

hotspot

leisure time

explore

explore